Jin et al. demonstrated the activation of cdk4 triggers and inhibitors of cdk4 for the prevention/treatment of Non-alcoholic Fatty Liver Disease [31]. This evidence concerns the gene CDK4 and metabolic dysfunction-associated steatotic liver disease.